Evidence map›Paper›PMID 41807293›Full record

ArticleJournal of medicinal chemistry2026

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.

Ludivine Moine, Wei Hu, Alison Davis, Emanuele Perola, Jian Guo, Kevin Barvian, Yeon Sook Choi, Alexandra Grassian, Joseph L Kim, Omar K Ahmad and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ludivine MoineBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.ORCID 0009-0005-2482-8157
Wei HuBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.
Alison DavisBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.
Emanuele PerolaBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.
Jian GuoBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.
Kevin BarvianBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.
Yeon Sook ChoiBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.
Alexandra GrassianBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.
Joseph L KimBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.
Omar K AhmadBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-8040-4069
Thomas A DineenBlueprint Medicines Corporation, 45 Sidney St., Cambridge, Massachusetts 02139, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal stromal tumor (GIST) is the most common type of sarcoma of the gastrointestinal tract, with approximately 5000 new cases annually in the USA. Approximately 80% of GIST cases are driven by activating mutations in

Indexed as

Antineoplastic AgentsDrug DesignDrug Resistance, NeoplasmGastrointestinal Stromal TumorsImatinib MesylateProtein Kinase InhibitorsProto-Oncogene Proteins c-kitAnimalsCell Line, TumorHumansMiceMutationNaphthyridinesStructure-Activity RelationshipUreaXenograft Model Antitumor AssaysAntineoplastic AgentsImatinib MesylateKIT protein, humanNaphthyridinesProtein Kinase InhibitorsProto-Oncogene Proteins c-kitripretinibUrea

Identifiers

PMID41807293
PMCPMC13126683

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.